CD19 Antibody (PDR134): sc-53191
- CD19 Antibody (PDR134) is a mouse monoclonal IgM κ, cited in 1 publications, provided at 200 µg/ml
- raised against Pokeweek-stimulated Daudi and Raji cells of human origin
- recommended for detection of CD19 of human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- See CD19 (B-1): sc-390244 for CD19 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgGκ BP-HRP is the preferred secondary detection reagent for CD19 Antibody (PDR134) for WB applications. This reagent is now offered in a bundle with CD19 Antibody (PDR134) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
QUICK LINKS
SEE ALSO...
CD19 Antibody (PDR134) is a mouse monoclonal IgM kappa light chain antibody that detects CD19 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD19 is a crucial transmembrane glycoprotein that plays a significant role in B-cell development and function, as CD19 is selectively expressed on the surface of B-lymphocytes. CD19 contains two extracellular immunoglobulin-like domains, which are essential for interaction with other proteins and for initiating intracellular signaling cascades. Notably, CD19 is involved in activating pathways such as Ras and phosphatidylinositol 3-kinase, which are vital for B-cell activation and proliferation. CD19′s importance extends to forming functional complexes with other B-lymphocyte surface proteins, including integrin β1, CD21, and CD81, which collectively regulate B-cell development and enhance the immune response. CD19′s expression is maintained throughout B-cell maturation and persists even during the terminal differentiation of B-cells into plasma cells, underscoring CD19′s critical role in the adaptive immune system.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD19 Antibody (PDR134) References:
- CD19 as a molecular target in CNS autoimmunity. | Stüve, O., et al. 2014. Acta Neuropathol. 128: 177-90. PMID: 24993505
- Donor-derived CD19-targeted T cells in allogeneic transplants. | Magnani, CF., et al. 2015. Curr Opin Hematol. 22: 497-502. PMID: 26390165
- CD19-positive antibody-secreting cells provide immune memory. | Groves, CJ., et al. 2018. Blood Adv. 2: 3163-3176. PMID: 30478153
- CD19-directed CAR T cells gain traction. | Schuster, SJ. 2019. Lancet Oncol. 20: 2-3. PMID: 30518503
- A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. | Zanetti, SR., et al. 2022. Mol Ther. 30: 550-563. PMID: 34478871
- CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. | Bueno, C., et al. 2022. Blood. 140: 38-44. PMID: 35421218
- Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. | Lamble, AJ., et al. 2023. Blood Adv. 7: 575-585. PMID: 35482927
- Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. | Heard, A., et al. 2022. Nat Commun. 13: 3367. PMID: 35690611
- Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR. | Chen, X., et al. 2023. Cancer Immunol Res. 11: 150-163. PMID: 36409926
- Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display. | Ganji, M., et al. 2023. J Transl Med. 21: 891. PMID: 38066569
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD19 Antibody (PDR134) | sc-53191 | 200 µg/ml | $322.00 | |||
CD19 Antibody (PDR134): m-IgGκ BP-HRP Bundle | sc-552779 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD19 Antibody (PDR134) FITC | sc-53191 FITC | 200 µg/ml | $336.00 | |||
CD19 Antibody (PDR134) PE | sc-53191 PE | 200 µg/ml | $349.00 |